Jerry Wang

Dr. Jerry Wang is the Chief Scientific Officer and co-founder of I-Mab. He is leading the antibody discovery team to develop novel homegrown products with unique differentiation and first-in-class or best-in-class potential including lemzoparlimab (TJC4), uliledlimab (TJD5), etc. Dr. Wang is also leading the establishment of the translational research function of I-Mab in both China and the US to extensively and deeply explore the scientific mechanism of action, new combinations, and disease indication, as well as the appropriate clinical biomarkers for the core assets through both internal research and external collaboration.

Prior to joining I-Mab, Jerry worked in Neuro-inflammation DPU at GlaxoSmithKline (China) R&D Center and led multiple early discovery programs in autoimmune and neuroinflammatory diseases. Jerry has more than 15 years of research experience in basic immunology. He received his bachelor’s degree in Biology from Fudan University and his Ph.D. in Cell Biology from the Institute of Health Sciences, Chinese Academy of Sciences.